Genentech-Lodo sign agreement for soil-based drug discovery
Category: #health  By Paroma Bhattacharya  Date: 2018-05-12
  • share
  • Twitter
  • Facebook
  • LinkedIn

Genentech-Lodo sign agreement for soil-based drug discovery

Genentech, a Roche subsidiary, has reportedly signed a deal with Lodo Therapeutics for around $1 billion to employ the genome mining technology of Lodo for a new drug discovery. The deal seems to be a first for Lodo which has a backing of $17 million from Accelerator Life Science Partners.

If reports are to be believed, the alliance includes an upfront amount that has not been disclosed and commercial and research and development milestone payments of $969 million. In the event that the products reach the market, tiered royalties would be provided on sales, as per a clause included in the deal. The disease categories that will be pursued through the alliance have not yet been disclosed.

Sources state that natural products have been the starting point for various drugs – similar to how microorganisms and plants have been the origins of various drugs like aspirin, derived from willow bark. As per estimates, in the last few decades, around three quarters of cancer drugs and medicines to treat chronic diseases like type 2 diabetes have been derived from natural sources. Authentic reports suggest that the increased focus of pharmaceutical companies on large-molecule drugs and synthetic small-molecules drugs based on combinatorial chemistry has slowed down the investment in naturally sourced drugs. However, this collaboration seemingly points toward the renewal of interest in naturally sourced medicines.

In partnership with Genentech, Lodo will search for naturally-occurring small molecules from microbial DNA that exhibit therapeutic potential. The process of drug discovery can be slow and depends largely on chance. Lodo Therapeutics claims to be able to speed up the process with its genome-based approach that also helps in lowering the costs of finding compounds for drug resistant bacterial infections and cancer.

Reliable sources quoted co-founder of Lodo Therapeutics, David Pompliano, saying that the strategic collaboration of Lodo Therapeutics with one of the leaders of innovative drug technology clearly highlights the potential of the proprietary platform that Lodo represents and its value to advanced drug discovery initiatives.



About Author

Paroma Bhattacharya

Email: [email protected]   

Paroma Bhattacharya

Paroma currently works as a content developer for Algosonline, MSF and a series of alike platforms. Fortified with a post-graduation degree in Journalism and Mass Communication, she delved head long into a writing career, creating resourceful and information enriched ...

Read More

More News By Paroma Bhattacharya

E-grocery start-up HappyFresh secures up to US$20M in Series C funding
E-grocery start-up HappyFresh secures up to US$20M in Series C funding
By Paroma Bhattacharya

The Jakarta-based online grocery delivery start-up, HappyFresh, has made it to the front page for raising around USD 20 million in its latest Series C financing round. Reportedly, the fresh influx of capital will be us...

Walmart partners with Kidbox for its first apparel subscription box
Walmart partners with Kidbox for its first apparel subscription box
By Paroma Bhattacharya

Walmart has recently announced that it is launching its first subscription business for apparel and it would be solely for kids. The company has teamed up with Kidbox, a subscription-box company like StitchFix but focu...

Cube Chain launches Test-net that enables high TPS and fast searches
Cube Chain launches Test-net that enables high TPS and fast searches
By Paroma Bhattacharya

Innovative blockchain ecosystem Cube Chain has reportedly launched Test-net, a new platform that will permit high transaction per second (TPS) and fast searches when using blockchain. The new technology will also renov...